AstraZeneca: Alexion to present 11 progress reports

(CercleFinance.com) - AstraZeneca reports that Alexion, its rare disease division, will present data on its portfolio of treatments for generalised myasthenia gravis (gMG) at the American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) Annual Meeting and Myasthenia Gravis Foundation of America (MGFA) Scientific Session in Savannah, on 15-18 October 2024.


The company will present 11 abstracts, including clinical and real-world data, supporting the safety and efficacy of Ultomiris (ravulizumab) and Soliris (eculizumab) in treating patients with positive anti-acetylcholine receptor (AChR) antibodies.

Alexion said that these positive results demonstrate the potential of these treatments to improve medical outcomes and quality of life for patients, notably by reducing the use of corticosteroids.


Copyright (c) 2024 CercleFinance.com. All rights reserved.